More evolution of the evidence in asthma disease management--SMART versus GOAL clinical trials debate the cost-benefit of LABA while the value of leukotriene modifiers, particularly montelukast, is uncertain

哮喘疾病管理方面的证据不断更新——SMART 与 GOAL 临床试验就长效β2受体激动剂（LABA）的成本效益展开辩论，而白三烯调节剂（尤其是孟鲁司特）的价值尚不明确。